Dissociating SCFA's Dual Signaling Through GPR43/GPR41 Biased Agonism

Target: FFAR2, FFAR3, NLRP3 Composite Score: 0.670 Price: $0.70▲50.0% Citation Quality: Pending neurodegeneration Status: promoted

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

🧠 Neurodegeneration

✓ All Quality Gates Passed

Quality Report Card click to collapse

Composite: 0.670

Top 30% of 1374 hypotheses

T5 Contested

Contradicted by evidence, under dispute

C+ Mech. Plausibility 15% 0.58 Top 63%

B+ Evidence Strength 15% 0.72 Top 20%

B+ Novelty 12% 0.75 Top 35%

D Feasibility 12% 0.38 Top 84%

B Impact 12% 0.60 Top 62%

C Druggability 10% 0.45 Top 70%

C+ Safety Profile 8% 0.55 Top 48%

B Competition 6% 0.62 Top 60%

C Data Availability 5% 0.48 Top 77%

C+ Reproducibility 5% 0.52 Top 65%

Evidence

7 supporting | 5 opposing

Citation quality: 75%

Debates

1 session B+

Avg quality: 0.70

Convergence

0.00 F 30 related hypothesis share this target

From Analysis:

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically relevant brain concentrations?

The debate identified a critical mechanistic gap between SCFA production by gut bacteria and α-synuclein disaggregation. While SCFAs cross the blood-brain barrier, their actual concentrations in brain tissue and direct effects on protein aggregation remain unvalidated, preventing therapeutic development. Source: Debate session sess_SDA-2026-04-01-gap-20260401-225155 (Analysis: SDA-2026-04-01-gap-20260401-225155)

→ View full analysis & debate transcript

Hypotheses from Same Analysis (1)

These hypotheses emerged from the same multi-agent debate that produced this hypothesis.

HDAC6 Activation as SCFA-Mediated Neuroprotective Mechanism

Score: 0.682 | Target: HDAC6, HSP90AA1

→ View full analysis & all 2 hypotheses

Description

Mechanistic Overview

...

Mechanistic Overview

Dissociating SCFA's Dual Signaling Through GPR43/GPR41 Biased Agonism starts from the claim that modulating FFAR2, FFAR3, NLRP3 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "# Engineering GPR41-Biased SCFA Analogs to Bypass GPR43-NLRP3 Pro-Aggregation Signaling ## Mechanism of Action Short-chain fatty acids (SCFAs), principally acetate (C2), propionate (C3), and butyrate (C4), are produced by microbial fermentation of dietary fiber in the gut and reach systemic circulation at concentrations in the high micromolar to low millimolar range. These metabolites serve as critical signaling molecules beyond their role as colonic energy substrates, engaging a family of G-protein-coupled receptors (GPCRs) that include free fatty acid receptors 2 and 3, more commonly designated GPR43 (FFAR2) and GPR41 (FFAR3), respectively. Both receptors are class A rhodopsin-like GPCRs with distinct coupling preferences that initiate fundamentally divergent downstream signaling cascades. This divergence forms the mechanistic foundation for the hypothesis that selective GPR41-biased agonism could uncouple beneficial metabolic and anti-inflammatory signaling from potentially detrimental pathways linked to protein aggregation in neurodegenerative disease. GPR43 couples preferentially to Gαq/11 and Gαi/o pathways, leading to mobilization of intracellular calcium, activation of phospholipase C (PLC), and generation of inositol trisphosphate (IP3) and diacylglycerol (DAG), alongside inhibition of adenylyl cyclase and suppression of cyclic AMP (cAMP). This dual coupling architecture enables GPR43 to activate protein kinase C (PKC) isoforms, stimulate mitogen-activated protein kinase (MAPK) signaling cascades including ERK1/2 and p38, and promote nuclear translocation of transcription factors such as NF-κB. Critically, GPR43 activation has been shown to prime and activate the NLRP3 inflammasome through a Gαq-PLC-PKC-NF-κB axis, leading to caspase-1 activation and maturation of pro-inflammatory cytokines IL-1β and IL-18. The mechanistic link between GPR43 and NLRP3 is particularly relevant in the central nervous system (CNS), where microglial expression of both GPR43 and NLRP3 creates a molecular interface through which SCFAs may potentiate neuroinflammatory signaling. In vitro studies using murine microglial cell lines have demonstrated that acetate and propionate can significantly increase NLRP3 inflammasome activation markers, including ASC speck formation and IL-1β release, in a GPR43-dependent manner. In contrast, GPR41 couples almost exclusively through Gαi/o, achieving potent inhibition of adenylyl cyclase and robust suppression of cAMP-dependent protein kinase A (PKA) signaling. GPR41 engagement also activates AMP-activated protein kinase (AMPK), a central metabolic regulator that promotes mitochondrial biogenesis, enhances autophagy, and exerts anti-inflammatory effects through inhibition of NF-κB transcriptional activity. GPR41 is expressed in sympathetic neurons, enteroendocrine cells, and — importantly — in astrocytes and certain microglial populations within the CNS, where its activation has been associated with suppression of pro-inflammatory cytokine production. The GPR41-AMPK axis promotes lysosomal acidification and autophagic flux, processes that are essential for the clearance of misfolded proteins including α-synuclein, tau, and amyloid-β. This mechanistic distinction is central to the hypothesis: while GPR43-mediated SCFA signaling may drive NLRP3-dependent neuroinflammation that potentiates protein aggregation, GPR41-biased signaling may enhance autophagic clearance and suppress inflammatory cascades without triggering the pro-aggregation NLRP3 pathway. The concept of biased agonism in GPCR pharmacology provides the therapeutic logic for this approach. Biased ligands preferentially stabilize a specific receptor conformational state that favors one downstream signaling pathway over another. For GPR41/GPR43, this distinction is structurally tractable given that the two receptors share only approximately 30% sequence homology in their orthosteric binding pockets. Propionate and butyrate activate both receptors with comparable potency, but subtle modifications at the carboxylate head group and alkyl chain length can confer selectivity for GPR41 over GPR43. An engineered GPR41-biased SCFA analog would aim to retain the beneficial autophagy-promoting, anti-inflammatory, and neuroprotective effects mediated through GPR41-Gαi/o-AMPK signaling while avoiding activation of the GPR43-Gαq-NF-κB-NLRP3 inflammasome axis implicated in aggregation pathology. ## Evidence Base The foundational evidence linking SCFAs to neuroinflammation and protein aggregation in neurodegenerative disease is derived from germ-free (GF) animal studies and microbiota-depletion experiments. GF mice exhibit significantly reduced hippocampal SCFA concentrations and display marked cognitive deficits and social behavioral impairments that are partially reversed by supplementation with a SCFA mixture (acetate, propionate, and butyrate). Transcriptomic analyses of GF mouse brains reveal upregulation of genes associated with microglial activation and innate immune signaling, consistent with the hypothesis that gut-derived SCFAs are essential for maintaining immune quiescence in the CNS. In the context of protein aggregation, a landmark 2019 study published in Cell Host & Microbe demonstrated that microbiota depletion in the MPTP mouse model of Parkinson's disease attenuated microglial activation and reduced α-synuclein pathology, effects that were abrogated by SCFA supplementation, indicating that SCFAs can potentiate aggregation in a microglia-dependent manner. This finding establishes the SCFA-NLRP3-microglial axis as a mechanistic candidate in synucleinopathy. GPR43 expression in the CNS has been documented in multiple species. Quantitative PCR and immunohistochemistry studies in human post-mortem brain tissue have detected GPR43 transcripts and protein in cortical gray matter, the substantia nigra, and the enteric nervous system. In mouse models, GPR43 is expressed in Iba1-positive microglia, where its activation by acetate has been shown to increase expression of NLRP3 inflammasome components and enhance caspase-1 activity. Genetic deletion of GPR43 in the 5×FAD Alzheimer's disease mouse model reduced microglial inflammatory activation and attenuated amyloid-β plaque burden, providing direct evidence that GPR43 signaling contributes to disease-relevant pathology. Conversely, GPR41 knockout mice exhibit exacerbated neuroinflammation following lipopolysaccharide challenge, suggesting that GPR41 signaling is essential for maintaining immune homeostasis. The divergent phenotypes of GPR43 and GPR41 knockout mice provide strong genetic evidence for the therapeutic potential of selective GPR41 agonism. SCFA concentrations are measurably altered in neurodegenerative disease patient populations. Plasma propionate and butyrate levels are reduced in early-stage Parkinson's disease patients relative to age-matched controls, while acetate concentrations are elevated in the cerebrospinal fluid (CSF) of patients with Alzheimer's disease. Fecal SCFA levels are similarly reduced in Parkinson's disease cohorts, correlating with disease severity as measured by the Unified Parkinson's Disease Rating Scale (UPDRS) and the Hoehn and Yahr staging system. These observational findings suggest that SCFA bioavailability is perturbed in neurodegeneration, though whether this reflects a cause or consequence of disease remains unresolved. Importantly, SCFA supplementation trials in animal models of Alzheimer's and Parkinson's disease have yielded conflicting results, with some studies reporting improved cognitive performance and reduced aggregation and others finding no benefit or even worsened outcomes. The mechanistic explanation for this heterogeneity may lie in the differential activation of GPR43 versus GPR41: mixed SCFA cocktails that activate both receptors simultaneously may inadvertently drive the pro-inflammatory, aggregation-promoting GPR43 pathway. Emerging structural biology data support the feasibility of engineering selective GPR41 agonists. Cryo-electron microscopy structures of GPR41 and GPR43 in both agonist-bound and inactive states have revealed distinct conformational signatures in the orthosteric pocket that can be exploited for selective drug design. In particular, GPR41 possesses a deeper, more hydrophobic binding cavity that accommodates longer alkyl chains, enabling the design of propionate analogs with modifications at the C3 position that sterically hinder GPR43 engagement while retaining GPR41 potency. ## Clinical Relevance Translating GPR41-biased SCFA analogs to human neurodegenerative disease would address a significant unmet need in neurotherapeutic development. Current disease-modifying approaches for Alzheimer's disease, Parkinson's disease, and related synucleinopathies are limited by inadequate target engagement, poor CNS penetration, or unacceptable off-target effects. A biased GPR41 agonist offers a mechanistically novel strategy that targets the gut-brain axis at the level of host-microbiome metabolic interaction, providing a distinct therapeutic hypothesis from existing amyloid-targeting, tau-targeting, or alpha-synuclein-targeting approaches. Patient populations most likely to benefit would include individuals with early-stage neurodegenerative disease who retain measurable peripheral SCFA production capacity and whose disease phenotype is associated with NLRP3-driven neuroinflammation. Subgroups defined by gut microbiome dysbiosis, elevated peripheral IL-1β or IL-18 levels, or positron emission tomography (PET) evidence of microglial activation (using translocator protein [TSPO] radioligands) would represent mechanistically aligned cohorts. In Parkinson's disease, where the NLRP3 inflammasome has been implicated in the propagation of α-synuclein pathology from the enteric nervous system to the CNS via the vagus nerve, a GPR41-biased agonist with adequate gut and CNS exposure could potentially interrupt this axis at both the enteric and central levels. Biomarker strategies for target engagement could include measuring plasma AMPK phosphorylation as a pharmacodynamic readout of GPR41 activation, CSF IL-1β and IL-18 concentrations as indicators of NLRP3 inhibition, and neurofilament light chain (NfL) as a downstream marker of neuroaxonal integrity. In Alzheimer's disease, GPR41-biased agonism may complement anti-amyloid approaches by enhancing microglial-mediated clearance of amyloid plaques through the AMPK-autophagy axis while simultaneously suppressing the NLRP3-driven chronic neuroinflammation that contributes to neuronal loss. Human studies would need to establish GPR41 and GPR43 expression patterns across brain regions and cell types relevant to each disease indication, as expression may vary with disease stage and could influence therapeutic response. ## Therapeutic Implications The therapeutic advantage of a GPR41-biased agonist over conventional SCFAs or non-selective SCFA derivatives lies in its capacity to achieve mechanistic specificity that broad-spectrum SCFA supplementation cannot. Native SCFAs activate both GPR41 and GPR43 in a concentration-dependent manner that varies with receptor expression levels and tissue distribution, creating a pharmacological profile that inherently combines beneficial and potentially deleterious signaling. A biased analog would allow for dose-dependent GPR41 engagement without the confounding activation of GPR43-driven NLRP3 signaling, enabling a cleaner therapeutic index. From a pharmacokinetic standpoint, native SCFAs suffer from rapid systemic absorption, extensive first-pass metabolism, and limited blood-brain barrier (BBB) penetration. Acetate achieves brain concentrations estimated at less than 5% of plasma levels following peripheral administration, and propionate and butyrate show similarly restricted CNS availability. Engineering GPR41-biased analogs with enhanced lipophilicity, stability against SCFA oxidoreductases in the colon and liver, and optimized physicochemical properties for BBB transit would be essential development objectives. Strategies could include methylation of the carboxyl head group to increase passive diffusion across the BBB, incorporation of fluorinated alkyl chains to confer metabolic stability, and formulation with nanoparticle delivery systems designed for receptor-mediated transport. Dosing considerations would require characterization of GPR41 receptor occupancy versus downstream AMPK activation to establish a pharmacokinetic-pharmacodynamic relationship distinct from that of non-selective SCFA supplementation. Safety considerations for a GPR41-biased agonist would focus on off-target GPCR engagement, residual GPR43 activity at high doses, and systemic metabolic effects of sustained GPR41 activation in peripheral tissues, including enteroendocrine cells and adipocytes. GPR41 agonism stimulates peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) release from intestinal L-cells, which would provide an additional benefit of reduced appetite and improved glucose homeostasis but could also cause gastrointestinal adverse effects such as nausea and altered motility. The peripheral metabolic benefits of GPR41 agonism may be advantageous in neurodegenerative disease patients, given the established links between metabolic dysfunction and accelerated neurodegeneration. ## Potential Limitations The most significant risk in developing GPR41-biased SCFA analogs is the incomplete characterization of GPR43's role in human neurodegeneration. The majority of mechanistic evidence implicating GPR43-NLRP3 signaling in protein aggregation derives from mouse models, and species differences in microglial receptor expression, inflammasome component affinity, and SCFA metabolism limit direct translation. In particular, the relative abundance of GPR43 versus GPR41 on human microglia versus astrocytes remains to be quantified with receptor-specific antibodies validated in human tissue, and whether the GPR43-NLRP3 axis contributes significantly to human disease progression — as opposed to being a secondary amplifier of existing pathology — is not established. The hypothesis also faces a critical pharmacological challenge: achieving selective GPR41 agonism without any residual GPR43 activity is technically demanding given the overlapping ligand recognition profiles of the two receptors for endogenous SCFAs. Low-level GPR43 activation at therapeutic doses could paradoxically potentiate the NLRP3 pathway, particularly in regions where GPR43 expression is high. Counteracting this risk would require the development of highly selective compounds with GPR41 potency in the low nanomolar range and GPR43 potency greater than 10 μM — a selectivity window that has not yet been demonstrated for small-molecule SCFA analogs. Additional uncertainties include the dependence of the therapeutic effect on an intact gut microbiome for the production of endogenous SCFAs that may contribute to the overall pharmacological milieu, the potential for receptor desensitization or internalization with chronic GPR41 agonism, and the absence of validated pharmacodynamic biomarkers for GPR41 target engagement in the human CNS. Definitive validation would require demonstration of GPR41-dependent signaling in human iPSC-derived microglia and astrocytes, establishment of CSF and plasma biomarker endpoints that correlate with target engagement, and Phase I/IIa trials" Framed more explicitly, the hypothesis centers FFAR2, FFAR3, NLRP3 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating FFAR2, FFAR3, NLRP3 or the surrounding pathway space around Short-chain fatty acid / GPCR signaling can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.72, novelty 0.75, feasibility 0.38, impact 0.60, mechanistic plausibility 0.58, and clinical relevance 0.00.

Molecular and Cellular Rationale

The nominated target genes are `FFAR2, FFAR3, NLRP3` and the pathway label is `Short-chain fatty acid / GPCR signaling`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: FFAR2 (Free Fatty Acid Receptor 2, also known as GPR43) is a G-protein coupled receptor for short-chain fatty acids (SCFAs: acetate, propionate, butyrate) produced by gut microbiota. In brain, FFAR2 is expressed in microglia, astrocytes, and neurons. SCFAs through FFAR2 regulate neuroinflammation, microglial maturation, and blood-brain barrier integrity. In AD, SCFA-FFAR2 signaling is impaired, contributing to neuroinflammation. Butyrate (FFAR2 agonist) has anti-inflammatory and cognitive-enhancing effects. | FFAR3 (Free Fatty Acid Receptor 3, also known as GPR41) is a G-protein coupled receptor for short-chain fatty acids (SCFAs), with highest affinity for propionate. In brain, FFAR3 is expressed in neurons and enterochromaffin cells, modulating sympathetic nervous system activation. FFAR3 is a therapeutic target for metabolic and inflammatory conditions. In AD, FFAR3 signaling may contribute to gut-brain axis modulation of neuroinflammation. | NLRP3 (NOD-Like Receptor Family Pyrin Domain Containing 3, also known as NALP3 or cryopyrin) is an inflammasome component that activates caspase-1, leading to maturation and release of IL-1beta and IL-18. In brain, NLRP3 is expressed in microglia and to a lesser extent astrocytes. In AD, NLRP3 inflammasome is chronically activated by amyloid-beta oligomers, driving neuroinflammation via IL-1beta release. NLRP3 deficiency or inhibition protects against amyloid pathology and cognitive deficits in mouse models. This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of FFAR2, FFAR3, NLRP3 or Short-chain fatty acid / GPCR signaling is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

SCFAs exacerbate motor/gastrointestinal dysfunction via GPR43-NLRP3 pathway, intensifying α-syn pathology. Identifier 39904963. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

GPR43/GPR41 heterodimerization detected (STRING score: 0.575). This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

NLRP3 inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration. Identifier 30381407. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

SCFA mixture (including acetate, propionate, butyrate) exacerbates α-synuclein via GPR43-NLRP3. Identifier 39904963. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Lychee (Litchi chinensis Sonn.) Pulp Phenolics Activate the Short-Chain Fatty Acid-Free Fatty Acid Receptor Anti-inflammatory Pathway by Regulating Microbiota and Mitigate Intestinal Barrier Damage in Dextran Sulfate Sodium-Induced Colitis in Mice. Identifier 33533603. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Gut Microbiota-Derived Lipopolysaccharides and Short-Chain Fatty Acids Regulate Immune Responses via FFAR2/FFAR3 in Lung Ischemia-Reperfusion Injury. Identifier 41031863. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

GPR43 couples to both Gq and Gi/o depending on cellular context; oversimplifies SCFA receptor biology. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Propionate is most potent GPR43 agonist AND also activates GPR41; pharmacologically challenging to engineer GPR41-biased analogs. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

GPR43 expression in brain is substantially lower than GPR41; neuronal/microglial GPR43 relevance in PD uncertain. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

'Neuroprotective GPR41 effect' is not defined; no mechanism, downstream pathway, or citation provided. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

SCFA-mediated neuroprotection via propionate reported through different pathways (osteocalcin-mediated). Identifier 33517890. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.7013`, debate count `1`, citations `12`, predictions `9`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.
No clinical-trial summary is attached to this row yet. That should not be mistaken for a clean slate; it means translational diligence still needs to be done, especially if adjacent pathways have already failed for exposure, tolerability, or endpoint-selection reasons.
For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates FFAR2, FFAR3, NLRP3 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "Dissociating SCFA's Dual Signaling Through GPR43/GPR41 Biased Agonism".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting FFAR2, FFAR3, NLRP3 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["α-Synuclein Misfolding"] --> B["Oligomer Formation"]
    B --> C["Prion-like Spreading"]
    C --> D["Dopaminergic Neuron Loss"]
    D --> E["Motor & Cognitive Symptoms"]
    F["FFAR2 Modulation"] --> G["Aggregation Inhibition"]
    G --> H["Enhanced Clearance"]
    H --> I["Dopaminergic Preservation"]
    I --> J["Functional Recovery"]
    style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style F fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style J fill:#1b5e20,stroke:#81c784,color:#81c784

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

12 citations 7 with PMID Validation: 75% 7 supporting / 5 opposing

✓ For (7)

No supporting evidence

No opposing evidence

(5) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 12CLIN 0GENE 0EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
SCFAs exacerbate motor/gastrointestinal dysfunctio…	Supporting	MECH	-	-	-	-	PMID:39904963	-
GPR43/GPR41 heterodimerization detected (STRING sc…	Supporting	MECH	-	-	-	-	-	-
NLRP3 inflammasome inhibition prevents α-synuclein…	Supporting	MECH	-	-	-	-	PMID:30381407	-
SCFA mixture (including acetate, propionate, butyr…	Supporting	MECH	-	-	-	-	PMID:39904963	-
Lychee (Litchi chinensis Sonn.) Pulp Phenolics Act…	Supporting	MECH	J Agric Food Ch…	-	2021	-	PMID:33533603	-
Gut Microbiota-Derived Lipopolysaccharides and Sho…	Supporting	MECH	Ann N Y Acad Sc…	-	2025	-	PMID:41031863	-
Bacteroides coprocola protects dopaminergic neuron…	Supporting	MECH	Transl Neurodeg…	-	2026	-	PMID:41761283	-
GPR43 couples to both Gq and Gi/o depending on cel…	Opposing	MECH	-	-	-	-	-	-
Propionate is most potent GPR43 agonist AND also a…	Opposing	MECH	-	-	-	-	-	-
GPR43 expression in brain is substantially lower t…	Opposing	MECH	-	-	-	-	-	-
'Neuroprotective GPR41 effect' is not de…	Opposing	MECH	-	-	-	-	-	-
SCFA-mediated neuroprotection via propionate repor…	Opposing	MECH	-	-	-	-	PMID:33517890	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 7

SCFAs exacerbate motor/gastrointestinal dysfunction via GPR43-NLRP3 pathway, intensifying α-syn pathology

PMID:39904963

GPR43/GPR41 heterodimerization detected (STRING score: 0.575)

NLRP3 inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration

PMID:30381407

SCFA mixture (including acetate, propionate, butyrate) exacerbates α-synuclein via GPR43-NLRP3

PMID:39904963

Lychee (Litchi chinensis Sonn.) Pulp Phenolics Activate the Short-Chain Fatty Acid-Free Fatty Acid Receptor An…▼

J Agric Food Chem · 2021 · PMID:33533603

Gut Microbiota-Derived Lipopolysaccharides and Short-Chain Fatty Acids Regulate Immune Responses via FFAR2/FFA…▼

Gut Microbiota-Derived Lipopolysaccharides and Short-Chain Fatty Acids Regulate Immune Responses via FFAR2/FFAR3 in Lung Ischemia-Reperfusion Injury.

Ann N Y Acad Sci · 2025 · PMID:41031863

Bacteroides coprocola protects dopaminergic neurons in rotenone-induced Parkinson's disease mouse model by mod…▼

Bacteroides coprocola protects dopaminergic neurons in rotenone-induced Parkinson's disease mouse model by modulating gut microbiota dysbiosis and inhibiting the NLRP3 signaling pathway.

Transl Neurodegener · 2026 · PMID:41761283

✗ Opposing Evidence 5

GPR43 couples to both Gq and Gi/o depending on cellular context; oversimplifies SCFA receptor biology

Propionate is most potent GPR43 agonist AND also activates GPR41; pharmacologically challenging to engineer GP…▼

Propionate is most potent GPR43 agonist AND also activates GPR41; pharmacologically challenging to engineer GPR41-biased analogs

GPR43 expression in brain is substantially lower than GPR41; neuronal/microglial GPR43 relevance in PD uncerta…▼

GPR43 expression in brain is substantially lower than GPR41; neuronal/microglial GPR43 relevance in PD uncertain

'Neuroprotective GPR41 effect' is not defined; no mechanism, downstream pathway, or citation provided

SCFA-mediated neuroprotection via propionate reported through different pathways (osteocalcin-mediated)

PMID:33517890

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Gap Analysis | 4 rounds | 2026-04-12 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Mechanistically-Specific Hypotheses: SCFAs and α-Synuclein Aggregation

Hypothesis 1: SCFA-Mediated TFEB Nuclear Translocation via Class I HDAC Inhibition Drives Autophagic α-Synuclein Clearance

Mechanism: Butyrate (particularly at 1-2 mM colonic concentrations) inhibits class I HDACs (HDAC1/2/3) in neurons, relieving HDAC6-mediated repression of TFEB (Transcription Factor EB) transcriptional activity. TFEB activation upregulates a suite of lysosomal biogenesis genes including LAMP1, LAMP2, CTSD (cathepsin D), and ATP6V1H, enhancing autophagosome-lysosome fusion and se

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Skeptic's Evaluation: SCFA and α-Synuclein Hypotheses

Hypothesis 1: TFEB Nuclear Translocation via Class I HDAC Inhibition

Strongest Specific Weakness

Mechanistic gap in the HDAC6→TFEB axis: The hypothesis asserts "relieving HDAC6-mediated repression of TFEB" without specifying the nature of this repression or citing primary literature establishing this interaction. HDAC6 is primarily a cytoplasmic deacetylase involved in aggresome-autophagy dynamics (PMIDs: 15814717, 17604720). A direct transcriptional repression mechanism linking HDAC6 to TFEB nuclear import has not, to

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Domain Expert Response: Translational Evaluation of SCFA-α-Synuclein Hypotheses

Preliminary Context: Disease Domain Clarification

I must first flag a critical mismatch in framing. The therapeutic hypotheses concern α-synuclein aggregation, which is the pathological hallmark of Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB), not Alzheimer's disease (AD). While ~30-50% of AD patients exhibit Lewy body pathology at autopsy, and therapeutic mechanisms may have cross-disease relevance, the mechanistic claims require evaluation within synucleinopathy clinical

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

{
"ranked_hypotheses": [
{
"rank": 1,
"title": "Butyrate-Class I HDAC Inhibition-TFEB Pathway for α-Synuclein Clearance",
"mechanism": "Butyrate inhibits neuronal class I HDACs (HDAC1/2/3), relieving unknown repression on TFEB and triggering nuclear translocation that upregulates lysosomal biogenesis genes (LAMP1, LAMP2, CTSD) for autophagic aggregate clearance.",
"target_gene": "TFEB (primary), HDAC1/2/3 (upstream)",
"confidence_score": 0.55,
"novelty_score": 0.7,
"feasibility_score": 0.5,
"impact_score": 0.75,
"composite_score": 0

Price History

7d Trend

↔

Stable

7d Momentum

▼ 1.1%

Volatility

Low

0.0132

Events (7d)

⚡ Price Movement Log Recent 9 events

	Event	Price	Change	Source	Time
📊	Score Update	$0.525	▼ 13.5%	market_dynamics	2026-04-13 15:48
📄	New Evidence	$0.607	▲ 39.9%	market_dynamics	2026-04-13 15:41
💬	Debate Round	$0.434	▼ 25.2%	market_dynamics	2026-04-13 14:50
💬	Debate Round	$0.580	▲ 6.1%	market_dynamics	2026-04-13 13:33
📄	New Evidence	$0.547	▲ 25.6%	market_dynamics	2026-04-13 13:28
📊	Score Update	$0.435	▼ 4.0%	market_dynamics	2026-04-13 12:39
💬	Debate Round	$0.453	▼ 3.7%	market_dynamics	2026-04-13 10:57
📊	Score Update	$0.470	▲ 0.6%	market_dynamics	2026-04-13 07:43
📄	New Evidence	$0.468		market_dynamics	2026-04-13 06:11

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (9)

Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice.

Science translational medicine (2018) · PMID:30381407

No extracted figures yet

Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease.

Microbiome (2021) · PMID:33517890

No extracted figures yet

J Agric Food Chem (2021) · PMID:33533603

No extracted figures yet

Short-Chain Fatty Acid Aggregates Alpha-Synuclein Accumulation and Neuroinflammation via GPR43-NLRP3 Signaling Pathway in a Model Parkinson's Disease.

Molecular neurobiology (2025) · PMID:39904963

No extracted figures yet

Gut Microbiota-Derived Lipopolysaccharides and Short-Chain Fatty Acids Regulate Immune Responses via FFAR2/FFAR3 in Lung Ischemia-Reperfusion Injury.

Ann N Y Acad Sci (2025) · PMID:41031863

No extracted figures yet

Bacteroides coprocola protects dopaminergic neurons in rotenone-induced Parkinson's disease mouse model by modulating gut microbiota dysbiosis and inhibiting the NLRP3 signaling pathway.

Transl Neurodegener (2026) · PMID:41761283

No extracted figures yet

J Agric Food Chem (2021) · PMID:33533603

No extracted figures yet

Gut Microbiota-Derived Lipopolysaccharides and Short-Chain Fatty Acids Regulate Immune Responses via FFAR2/FFAR3 in Lung Ischemia-Reperfusion Injury.

Ann N Y Acad Sci (2025) · PMID:41031863

No extracted figures yet

Bacteroides coprocola protects dopaminergic neurons in rotenone-induced Parkinson's disease mouse model by modulating gut microbiota dysbiosis and inhibiting the NLRP3 signaling pathway.

Transl Neurodegener (2026) · PMID:41761283

No extracted figures yet

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically relevant brain concentrations? — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-12-gap-debate-20260410-113021-6fbc6da4. The debate identified a critical mechanistic gap between SCFA production by gut bacteria and α-synuclein dis …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

→ Browse all arenas & tournaments

KG Entities (3)

C3 C4 NLRP3

Related Hypotheses

TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegeneration

Score: 0.990 | neurodegeneration

TREM2-Dependent Microglial Senescence Transition

Score: 0.950 | neurodegeneration

PLCG2 Allosteric Modulation as a Precision Therapeutic for TREM2-Dependent Microglial Dysfunction

Score: 0.941 | neurodegeneration

Multi-Biomarker Composite Index Surpassing Amyloid PET for Treatment Response Prediction

Score: 0.933 | neurodegeneration

CYP46A1 Gene Therapy for Age-Related TREM2-Mediated Microglial Senescence Reversal

Score: 0.921 | neurodegeneration

Estimated Development

Estimated Cost

Timeline

8.0 years

🧪 Falsifiable Predictions (9)

9 total 0 confirmed 0 falsified

IF HEK293T cells engineered to co-express human GPR41 and GPR43 with GPCR signaling biosensors (cAMP GloSensor, calcium FLIM reporter, PKC translocation sensor) are stimulated with a panel of engineered GPR41-biased SCFA analogs at EC50 concentrations, THEN the GPR41-biased analogs will show selective Gαi/o pathway activation (cAMP suppression ≥80% of maximum) without detectable Gαq/11-mediated calcium flux (≤5% of GPR43-selective control) or PKC membrane translocation (≤10% of GPR43-selective control), using a series of propionate derivatives modified at the C2 and C3 positions.

pending conf: 0.85

Expected outcome: GPR41-biased analogs will exhibit ≥80% Gαi/o coupling with ≤10% Gαq/11 activation, demonstrating functional selectivity that predicts reduced NLRP3 priming in downstream neural models.

Falsified by: If any GPR41-biased analog triggers Gαq/11-mediated calcium mobilization (>15% of control) or PKC activation (>20% of control), the structural modifications fail to achieve true biased agonism and the hypothesis cannot be tested in downstream models—the selectivity requirement is falsified at the receptor signaling level.

Method: Stable cell lines co-expressing GPR41-pECFP and GPR43-pYFP with biosensor constructs will be generated. Concentration-response curves (10nM-1mM) will be measured for each analog. Gαi/o activity quantified via cAMP accumulation assay. Gαq/11 activity measured via Fluo-4 calcium imaging. PKC translocation monitored via FRET-based PKC translocation reporter. Data analyzed via Morphic and Prism for bias factor calculation using operational models.

IF GPR41-biased SCFA analogs (selective for Gαi/o coupling) are applied to dual-expressing GPR43/GPR41 HEK293 cells, THEN cAMP inhibition will occur without detectable intracellular calcium mobilization or PKC phosphorylation within 15 minutes, using engineered HEK293T cells with separate GPR43 and GPR41 expression cassettes.

pending conf: 0.82

Expected outcome: cAMP suppression ≥70% (GPR41 activation) with calcium response <10% of non-selective SCFA (C3) control, demonstrating functional GPR41 bias and absence of GPR43 engagement.

Falsified by: If GPR41-biased analogs produce ≥30% calcium mobilization or ≥30% PKC phosphorylation relative to propionate (C3) controls, the selectivity hypothesis is disproven—this indicates unacceptably high GPR43 activation.

Method: CRISPR-untagged receptor overexpression in HEK293T, followed by concurrent cAMP BRET sensor measurements and Fluo-4 calcium imaging upon compound application. Dose-response curves (1nM–10mM) for test analogs vs. C2/C3/C4 natural SCFAs.

IF BV2 microglial cells are pre-treated with GPR41-biased SCFA analogs versus non-selective acetate, THEN NLRP3 inflammasome activation markers (caspase-1 FLICA signal, ASC speck formation, IL-1β secretion) will be reduced to baseline levels within 6 hours post-NLRP3 trigger (ATP 5mM), while anti-inflammatory IL-10 remains elevated, using primary murine microglia.

pending conf: 0.78

Expected outcome: Caspase-1 activity reduced ≥60%, ASC specks decreased ≥50%, IL-1β release reduced ≥70% compared to C3 propionate treatment; IL-10 levels unchanged or increased (maintained anti-inflammatory signaling).

Falsified by: If GPR41-biased analogs produce NLRP3 activation levels statistically indistinguishable from non-selective SCFAs (p>0.05, ANOVA with Bonferroni correction), the hypothesis that GPR41 bias uncouples inflammasome priming is disproven.

Method: LPS priming (100ng/mL, 4h) followed by 1h analog pre-treatment, then ATP challenge. Measure: FLICA caspase-1 assay (flow cytometry), ASC-mClover immunostaining (confocal), IL-1β/IL-10 ELISA, and corresponding caspase-1/cell death assay.

IF primary murine microglia or iPSC-derived neural cultures are treated with a GPR41-biased SCFA analog (selective FFAR3 agonist at 100μM) versus an equipotent pan-agonist (acetate at 1mM) for 48 hours under neuroinflammatory conditions, THEN the GPR41-biased treatment group will exhibit significantly reduced NLRP3 inflammasome activation markers (caspase-1 activity ≤40% of pan-agonist control, IL-1β secretion ≤35% of pan-agonist control) while retaining comparable anti-inflammatory signaling (p-AMPK/AMPK ratio increase ≥70% of pan-agonist response) using a GPR41-biased synthetic SCFA analog in microglial BV-2 cells or primary cultures.

pending conf: 0.78

Expected outcome: GPR41-biased agonist will reduce NLRP3 activation markers by ≥60% compared to pan-SCFAs while maintaining ≥70% of the anti-inflammatory downstream effects, demonstrating selective pathway dissociation.

Falsified by: If GPR41-biased agonist produces NLRP3 activation equivalent to or greater than pan-agonist (>80% of control), the hypothesis is disproven—the pro-aggregation signaling is not exclusively GPR43-dependent and selective GPR41 agonism cannot bypass this pathway.

Method: Primary microglia cultured from C57BL/6 mice or human iPSC-derived microglial cultures will be pre-treated with LPS (100 ng/mL, 4h) to prime the NLRP3 inflammasome, then co-treated with test compounds. NLRP3 activation will be quantified via Caspase-Glo 1st assay, IL-1β ELISA, and ASC speck immunofluorescence. GPR41 engagement will be confirmed via cAMP suppression assay.

IF primary mouse microglia are treated with GPR41-biased SCFA analog (10 μM) versus non-selective acetate (10 mM) THEN NLRP3 inflammasome activation will be significantly reduced (caspase-1 activity <20% of non-selective agonist control) within 24 hours using primary mouse microglia cultures

pending conf: 0.75

Expected outcome: Caspase-1 activity (measured by FLICA assay) and IL-1β release (ELISA) will be reduced by >80% in GPR41-biased analog treatment group compared to equimolar non-selective SCFA, despite equivalent Gαi/o-mediated cAMP inhibition in both conditions

Falsified by: If GPR41-biased analog produces equivalent (>90%) NLRP3 activation (caspase-1 activity, IL-1β release) compared to non-selective SCFA at matching concentrations, the hypothesis that GPR41 bias can uncouple GPR43-NLRP3 signaling is falsified

Method: Primary microglia cultured from C57BL/6 mice will be stimulated with synthetic GPR41-biased SCFA analog and compared to physiological acetate/propionate mixture. NLRP3 activation will be quantified via Caspase-Glo 1 inflammasome assay, IL-1β/IL-18 ELISA, ASC speck formation via immunofluorescence, and immunoblot for NLRP3, cleaved caspase-1, and gasdermin D

IF transgenic mice exhibiting α-synuclein aggregation (α-synuclein A53T model) are administered daily intraperitoneal injections of a GPR41-biased SCFA analog (10 mg/kg) versus sodium acetate (200 mg/kg) or vehicle for 8 weeks beginning at 8 weeks of age, THEN the GPR41-biased group will demonstrate reduced microglial NLRP3 activation (Iba1+/NLRP3+ colocalization ≤50% of acetate group), decreased α-synuclein oligomerization (ELISA ≥40% reduction in insoluble oligomer fraction), and improved motor performance (rotarod latency ≥85% of vehicle-treated age-matched controls) compared to the pan-agonist treatment group, using C57BL/6J-A53T α-synuclein transgenic mice.

pending conf: 0.72

Expected outcome: GPR41-biased agonist will reduce α-synuclein aggregation markers by ≥40% and microglial NLRP3 activation by ≥50% compared to acetate treatment, while maintaining equivalent anti-inflammatory and metabolic benefits.

Falsified by: If the GPR41-biased agonist shows equivalent or increased protein aggregation (oligomer levels >90% of acetate group) and equivalent NLRP3 activation despite selective GPR41 engagement, the hypothesis is disproven—the aggregation pathway operates independently of receptor-specific signaling.

Method: Mice will be randomly assigned to treatment groups (n=12 per group). Motor function assessed via accelerated rotarod weekly. At endpoint, brains will be harvested for: (1) ELISA quantification of α-synuclein oligomers in striatal tissue, (2) immunohistochemistry for Iba1/NLRP3/ASC specks, (3) Western blot for phosphorylated α-synuclein (Ser129). Plasma SCFA levels and peripheral immune markers will be monitored biweekly.

IF 5xFAD transgenic mice (Alzheimer's model) receive oral GPR41-biased SCFA analog (50 mg/kg/day) for 8 weeks THEN microglial NLRP3 activation and amyloid plaque load will be significantly reduced compared to vehicle-treated 5xFAD mice using in vivo mouse model

pending conf: 0.72

Expected outcome: Brain tissue analysis will show: (1) >40% reduction in NLRP3/caspase-1 positive microglia (Iba1+ cells) via immunohistochemistry, (2) >30% reduction in Thioflavin-S positive amyloid plaque area, (3) reduced IL-1β and IL-18 in brain homogenates (ELISA), while systemic SCFA levels remain comparable to physiological range

Falsified by: If GPR41-biased analog treatment shows no significant reduction (p>0.05) in microglial NLRP3 activation or amyloid plaque load compared to vehicle controls, or shows equivalent pathology to non-selective SCFA treatment, the hypothesis is falsified

Method: 3-month-old 5xFAD mice will be treated with GPR41-biased SCFA analog via oral gavage for 8 weeks. Endpoints: brain tissue collected for Iba1/NLRP3/caspase-1 immunofluorescence (confocal quantification), Thioflavin-S amyloid plaque area analysis, and cytokine measurements. Controls: vehicle, equimolar acetate, and GPR43-selective analog

IF 5xFAD Alzheimer's disease model mice receive chronic intraperitoneal GPR41-biased SCFA analog (10mg/kg, daily) for 12 weeks, THEN amyloid plaque burden (Thioflavin-S) and microglial NLRP3 activation (Iba1+NLRP3 colocalization) will be reduced ≥40% versus vehicle controls, while cognitive performance (Morris water maze latency) improves comparably to non-selective SCFA treatment, using age-matched 6-month-old 5xFAD mice.

pending conf: 0.68

Expected outcome: Amyloid plaque area fraction reduced ≥40%, NLRP3+ microglia decreased ≥50%, with water maze escape latency reduced to ≤80s (vs. >100s vehicle) and equivalent to C3 propionate-treated mice (positive comparator).

Falsified by: If GPR41-biased analog fails to reduce amyloid burden or NLRP3 activation (≤20% reduction, p>0.05) while showing comparable cognitive improvement to non-selective SCFAs, then GPR43-NLRP3 pathway contribution to aggregation is non-essential. If analog shows no cognitive benefit despite low NLRP3, then GPR41 anti-inflammatory signaling is insufficient for neuroprotection.

Method: Randomized vehicle vs. GPR41-analog vs. C3 propionate groups (n≥12/condition), 12-week treatment, followed by behavioral testing (MWM, Y-maze), then brain tissue harvest for Thioflavin-S plaque quantification, Iba1/NLRP3/LAMP2 immunohistochemistry, and cortex/hippocampus IL-1β/IL-18 multiplex assay.

IF neurons are co-cultured with microglia pre-treated with GPR41-biased SCFA analog versus GPR43-selective agonist THEN protein aggregation (α-synuclein fibril seeding) will be reduced by >50% within 72 hours using iPSC-derived neuron-microglia co-culture system

pending conf: 0.68

Expected outcome: Thioflavin-T fluorescence (aggregated protein), pSer129 α-synuclein puncta (immunocytochemistry), and neuronal viability (Calcein-AM/ethidium homodimer) will show significantly reduced aggregation and increased survival in GPR41-biased condition compared to GPR43-selective condition

Falsified by: If GPR41-biased analog treatment shows equivalent or increased protein aggregation and neurotoxicity compared to GPR43-selective agonist treatment, the hypothesis that GPR41 bias reduces pro-aggregation signaling is falsified

Method: Human iPSC-derived neurons (dopaminergic for Parkinson's model) will be co-cultured with iPSC-derived microglia-like cells. Pre-formed α-synuclein fibrils (10 μg/mL) will be added with or without SCFA analog pretreatment. Aggregation measured by Thioflavin-T assay, confocal microscopy for pSer129 α-synuclein, and neuronal viability by Live/Dead assay

Knowledge Subgraph (2 edges)

co discussed (2)

C3→NLRP3C4→NLRP3

3D Protein Structure

🧬 FFAR2 — Search for structure Click to search RCSB PDB

🔍 Searching RCSB PDB for FFAR2 structures...

Querying Protein Data Bank API

Source Analysis

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically relevant brain concentrations?

neurodegeneration | 2026-04-12 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Dissociating SCFA's Dual Signaling Through GPR43/GPR41 Biased Agonism

Hypotheses from Same Analysis (1)

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

Dimension Scores

✓ Supporting Evidence 7

✗ Opposing Evidence 5

Mechanistically-Specific Hypotheses: SCFAs and α-Synuclein Aggregation

Hypothesis 1: SCFA-Mediated TFEB Nuclear Translocation via Class I HDAC Inhibition Drives Autophagic α-Synuclein Clearance

Skeptic's Evaluation: SCFA and α-Synuclein Hypotheses

Hypothesis 1: TFEB Nuclear Translocation via Class I HDAC Inhibition

Strongest Specific Weakness

Domain Expert Response: Translational Evaluation of SCFA-α-Synuclein Hypotheses

Preliminary Context: Disease Domain Clarification

Price History

Clinical Trials (0)

📚 Cited Papers (9)

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

🔄 Related Hypotheses

Hypotheses from Same Analysis (1)

🧬 Same Target Gene / Disease (30)

KG Entities (3)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (9)

Knowledge Subgraph (2 edges)

co discussed (2)

3D Protein Structure

Source Analysis

Do SCFAs directly modulate α-synuclein aggregation in vivo at physiologically relevant brain concentrations?

Community Feedback